Infections in allogeneic bone marrow transplant recipients.

abstract：:Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer ...

journal_title：Seminars in oncology

authors： Oeffinger KC,Baxi SS,Novetsky Friedman D,Moskowitz CS

更新日期：2013-12-01 00:00:00

abstract：:In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

journal_title：Seminars in oncology

authors： Le Chevalier T

更新日期：2003-08-01 00:00:00

abstract：:Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recen...

journal_title：Seminars in oncology

authors： Loehrer PJ Sr

更新日期：1992-12-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00

abstract：:Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

journal_title：Seminars in oncology

authors： Saad F,Eastham J

更新日期：2010-06-01 00:00:00

abstract：:Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

journal_title：Seminars in oncology

authors： Mathew R,Messina JL

更新日期：2012-04-01 00:00:00

abstract：:A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

journal_title：Seminars in oncology

authors： Ettinger DS

更新日期：2005-04-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

journal_title：Seminars in oncology

authors： Moinpour CM

更新日期：1994-10-01 00:00:00

abstract：:Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

journal_title：Seminars in oncology

authors： Simone CB 2nd,Cengel KA

更新日期：2014-12-01 00:00:00

abstract：:A large body of work spanning the past decade has identified the molecular chaperone heat shock protein 90 (Hsp90) as a critical modulator of an extensive network of cellular signaling pathways. Many of the processes overseen by Hsp90 are deregulated in tumor cells, including cell cycle control, gene transcription, an...

journal_title：Seminars in oncology

authors： Cullinan SB,Whitesell L

更新日期：2006-08-01 00:00:00

abstract：:Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regimens against non-small cell lung cancer. Vinorelbine usually has been...

journal_title：Seminars in oncology

authors： Masters GA,Hoffman PC,Drinkard LC,Watson S,Samuels BL,Golomb HM,Vokes EE

更新日期：1996-04-01 00:00:00

abstract：:Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort...

journal_title：Seminars in oncology

authors： Rosso R,Amoroso D,Gardin G,Miglietta L,Guido T,Pace M,Repetto L,Pronzato P

更新日期：1991-04-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

journal_title：Seminars in oncology

authors： Vymazal J,Wong ET

更新日期：2014-10-01 00:00:00

abstract：:Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

journal_title：Seminars in oncology

authors： Vaupel P,Kelleher DK,Höckel M

更新日期：2001-04-01 00:00:00

abstract：:In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU re...

journal_title：Seminars in oncology

authors： Van Cutsem E,Blijham GH

更新日期：1999-02-01 00:00:00

abstract：:Choices of treatment for patients with estrogen receptor (ER) positive metastatic breast cancer refractory to first-line endocrine therapies include progestins, antiadrenal drugs, and androgens. These treatments should be administered sequentially to achieve maximum palliation of the disease. For ER positive patients ...

journal_title：Seminars in oncology

authors： Buzdar AU

更新日期：1988-06-01 00:00:00

abstract：:Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cance...

journal_title：Seminars in oncology

authors： Lazzeroni M,DeCensi A

更新日期：2016-02-01 00:00:00

abstract：:Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (Ie, Ta, Tl, and carcinoma in situ [CIS]) with specific objectives that include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging s...

journal_title：Seminars in oncology

authors： Nseyo UO,Lamm DL

更新日期：1996-10-01 00:00:00

abstract：:Non-platinum combination regimens have been developed for advanced non--small cell lung cancer using the novel and active agents docetaxel, gemcitabine, vinorelbine, and irinotecan. The aim of these combinations is to equal or exceed the survival benefits achieved with cisplatin doublets while minimizing toxicity. Of ...

journal_title：Seminars in oncology

authors： Rigas JR

更新日期：2001-06-01 00:00:00

abstract：:Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a deta...

journal_title：Seminars in oncology

authors： Fonseca R,Monge J

更新日期：2013-10-01 00:00:00

abstract：:Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. I...

journal_title：Seminars in oncology

authors： Jaeckle KA

更新日期：2014-08-01 00:00:00

abstract：:Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

journal_title：Seminars in oncology

authors： Arteaga CL,Khuri F,Krystal G,Sebti S

更新日期：2002-02-01 00:00:00

abstract：:We report the updated results of an intensive treatment protocol for children (< 18 years) and adults (> or = 18 years) with advanced B-cell lymphomas. The protocol consists of two chemotherapy regimens: A, consisting of cyclophosphamide, doxorubicin, vincristine and high-dose methotrexate (CODOX-M), and B, consisting...

journal_title：Seminars in oncology

authors： Adde M,Shad A,Venzon D,Arndt C,Gootenberg J,Neely J,Nieder M,Owen W,Seibel N,Wilson W,Horak ID,Magrath I

更新日期：1998-04-01 00:00:00

abstract：:Phase I trials of the intraperitoneal (IP) administration of cisplatin have demonstrated that the drug can be safely delivered by this route with a major increase in exposure (approximately tenfold to 15-fold) of the cavity to the cytotoxic agent compared with that of the systemic circulation. Phase I trials of IP cis...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1989-08-01 00:00:00

abstract：:Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion was inactive in HR...

journal_title：Seminars in oncology

authors： Hudes GR,Nathan FE,Khater C,Greenberg R,Gomella L,Stern C,McAleer C

更新日期：1995-10-01 00:00:00

abstract：:In order to correlate changes in morphology to changes in molecular attributes, we constructed a tissue microarray of thin and thick melanomas selected to represent progression from dysplasia to early and advanced melanoma. Hematoxylin and eosin (H&E) staining and immunohistology with antibodies to cyclin D1, p16, Ki6...

journal_title：Seminars in oncology

authors： Tuthill RJ,Reed RJ

更新日期：2007-12-01 00:00:00

abstract：:Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1995-04-01 00:00:00

abstract：:This study reports the effectiveness and side effects of intravenous ondansetron as a single-agent antiemetic therapy for patients receiving emetogenic cancer chemotherapy under a compassionate-use program for patients not enrolled in controlled clinical trials. Patients were > or = 7 years old and had uncontrolled na...

journal_title：Seminars in oncology

authors： Berry WR,House KW,Lee JT,Plagge PB,Meshad MW,Grapski R

更新日期：1992-12-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00